Halozyme, Baxter release positive PhIII results for a much-welcomed subcutaneous Gammagard Liquid
This article was originally published in Scrip
Executive Summary
Halozyme Therapeutics and its partner Baxter International have released positive top-line Phase III results showing that a subcutaneous formulation of Baxter's immune globulin Gammagard Liquid using technology from Halozyme met the primary endpoint in a trial to treat primary immunodeficiency (PI) disorders. The product is known as HyQ (immunoglobulin with rHuPH20).